Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — JP Morgan Global Healthcare Conference 2024
11 slides from Fresenius Medical Care's conference presentation, Jan 8, 2024
Slide 1: JP Morgan Global Healthcare Conference
JP Morgan Global Healthcare Conference Helen Giza, CEO & Chair of Management Board January 8, 2024 © Copyright
Slide 2: Safe harbor statement
Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conve
Slide 3: We are the leading kidney care company globally
We are the leading kidney care company globally Largest dialysis services network globally Market leader with products serving around half of the world’s dialysis patients Around 71 >4,000 341,000 Net Promoter dialysis centers Global Global dialysis patients Score #1 #1 Global in-center HD HHD #2 ma
Slide 4: Underlying business fundamentals intact
Underlying business fundamentals intact Extrapolation from 2020 to 2035 Ageing global population Hypertension Diabetes Dialysis patients +60% One out of four people worldwide has +40% +100% hypertension2 Global population People living People on maintenance aged 65+1 with diabetes3 dialysis4 0.75 bi
Slide 5: GLP-1 medications' assumed effects on the kidney disease population
GLP-1 medications’ assumed effects on the kidney disease population ESRD patients with significant co- Overall, GLP-1 medications are morbidity burden expected to have a balanced impact on ESRD patient volumes Expected long-term impact Cardio- Diabetes vascular ▪ GLP-1 help control T2D with proven b
Slide 6: Advancing in-center therapies globally with High Volume Hemodiafiltration (HVHDF)
Advancing in-center therapies globally with High Volume Hemodiafiltration (HVHDF) CONVICE Study A pragmatic, multinational, randomized, controlled trial With 100% adoption of HVHDF, mortality can be reduced by approximately (based on 2019 rates): Comparison of High-Volume Hemodiafiltration ▪ US HD p
Slide 7: Executing on our strategic plan
Executing on our strategic plan Unlock value as the leading kidney care company Global operating model Financial reporting with Structure Simplified governance with two segments enhanced transparency Capital Disciplined financial policy ROIC improvement focus allocation Operational FME25 efficiencie
Slide 8: 9M 2023 | Organic growth momentum continues
9M 2023 | Organic growth momentum continues Revenue | guidance base Operating income | guidance base in € million Margin in % 8.1% 7.3% 8.2% 6.5% +5% cc 14,401 14,466 in € million +14%cc +5% organic +162 -270 1,160 1,186 -244 1,052 942 9M 2022 9M 2023 9M 2022 9M 2023 Operating Income (guidance base)
Slide 9: 9M 2023 | Strong cash flow development
9M 2023 | Strong cash flow development in € million 9M 2023 9M 2022 Solid financing strategy Operating cash flow 1,910 1,568 ▪ Capital expenditures, net (430) (486) ▪ €650m Euro bond, maturing in Free cash flow 1,480 1,082 Nov. 2023, successfully refinanced by mix of long- ▪ Free cash flow after inv
Slide 10: Outlook | Earnings guidance upgraded
Outlook | Earnings guidance upgraded FY 2023 Revenue Operating income Low- to mid-single digit percentage growth Between 12 and 14 percent growth Prev.: Low-single digit percentage growth FY 2022 basis: EUR 19.4bn FY 2022 basis: EUR 1.54bn Further outlook By 2025 an improved operating income margin
Slide 11: Your questions are welcome.
Your questions are welcome. © Copyright
Fresenius Medical Care — JP Morgan Global Healthcare Conference 2024 on 6ix